Atos Medical AB
13
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.7%
1 terminated/withdrawn out of 13 trials
90.0%
+3.5% vs industry average
0%
0 trials in Phase 3/4
67%
6 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Post-operative Use of New Adhesive After Total Laryngectomy
Role: lead
Use of TrachPhone in Tracheostomized Patients
Role: lead
Long Term Effects of Heat and Moisture Exchangers (HMEs)
Role: lead
Clinical Feasibility of a New Voice Prosthesis
Role: lead
Evaluation of the Safety and Efficacy of Voice Prosthesis in Voice Reconstruction After Total Laryngectomy
Role: lead
Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis
Role: lead
Day/Night Regimen With Provox Life Heat and Moisture Exchangers
Role: lead
Assessment of the New Provox Life System for Pulmonary Health and Quality of Life After Total Laryngectomy
Role: lead
Clinical Feasibility of New Tracheoesophageal Puncture Set
Role: lead
Clinical Assessment of New Speaking Valve With Heat and Moisture Exchanger (HME) for Tracheotomized Patients
Role: lead
Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice Prosthesis
Role: lead
Long Term Use of the Provox Vega 22.5
Role: lead
Short-term Clinical Feasibility of the Provox XtraHMEs for Pulmonary Rehabilitation After Total Laryngectomy
Role: lead
All 13 trials loaded